Abstract:Objective: To investigate the expression level of the maternally expressed gene-3 ( MEG3 ) of the free long non-coding RNA (lncRNAs) in the plasma of Parkinson's disease (PD) patients and its relationship with the disease. Methods: Thirty PD patients (PD group) who treated at Xuanwu Hospital of Capital University of Medical Sciences between January 2017 and December 2019 were selected as the research objects and 30 healthy subjects were enrolled in the study during the same period as the control group. Cognitive function was assessed according to the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) were used to evaluate cognitive function, Non-Motor Symptoms Scale (NMSS) was used to evaluate severity of non-motor symptoms. The relative expression of lncRNAs MEG3 in plasma was measured by PCR, and the levels of neuron-specific enolase (NSE), nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in plasma were measured by ELISA, and the relationship with these all indexes was analyzed. Results: The NMSS score of PD group was significantly higher than that of the control group, while the MMSE and MoCA scores were significantly lower than that of the control group ( P < 0.05); The relative expression of lncRNAs MEG3 , NGF and BDNF levels of PD group were significantly lower than that of the control group, and NSE level was significantly higher than that of the control group ( P < 0.05); The H&Y stage and NMSS score in PD group were negatively correlated with the relative expression of lncRNAs MEG3 , the levels of NGF and BDNF ( P < 0.05), and positively correlated with NSE ( P < 0.05); The MMSE and MoCA scores in PD group were positively correlated with the relative expression of lncRNAs MEG3 , NGF, BDNF levels ( P < 0.05), and negatively correlated with NSE ( P < 0.05); The relative expression of lncRNAs MEG3 in PD group was positively correlated with NGF, BDNF levels ( P < 0.05), and negatively correlated with NSE ( P < 0.05). Conclusion: The expression of lncRNAs MEG3 in the plasma of PD patients was downregulated compared to that of healthy control subjects, and its expression level was closely related to the aggravation of non-motor symptoms, cognitive decline, and PD stage. These associations may reflect the synergism of the increase of NSE and decrease of NGF and BDNF levels, highlighting plasma lncRNA MEG3 as a new candidate biomarker of PD.

Downregulation of lncRNA MEG3 is involved in Parkinson’s disease

Association of the Plasma Long Non-coding RNA MEG3 With Parkinson's Disease

Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson’s disease based on integrative analysis

Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression

MEG 3 regulates the invasion and migration of lung cancer via targeting miR-219 a and through MAPK pathway

Downregulated Long Noncoding Rna Meg3 is Associated with Poor Prognosis and Promotes Cell Proliferation in Gastric Cancer

Long Non-Coding RNA MEG3 Downregulation Triggers Human Pulmonary Artery Smooth Muscle Cell Proliferation and Migration via the p53 Signaling Pathway

Downregulation of CHCHD2 may Contribute to Parkinson's Disease by Reducing Expression of NFE2L2 and RQCD1

Downregulation of MEG3 Promotes Neuroblastoma Development Through FOXO1-mediated Autophagy and Mtor-Mediated Epithelial-Mesenchymal Transition.

Long Noncoding RNA MEG3 Mediated Angiogenesis after Cerebral Infarction Through Regulating P53/nox4 Axis.

Early B Cell Factor 3 (EBF3) attenuates Parkinson's disease through directly regulating contactin-associated protein-like 4 ( CNTNAP4 ) transcription: An experimental study

MTERF3 Contributes to MPP+-induced Mitochondrial Dysfunction in SH-SY5Y Cells

LncRNA KCNQ1OT1 promotes NLRP3 inflammasome activation in Parkinson's disease by regulating pri-miR-186/mature miR-186/NLRP3 axis

Dysregulation of Circulatory Levels of lncRNAs in Parkinson’s Disease

Upregulated lncRNA small nucleolar RNA host gene 1 promotes 1‐methyl‐4‐phenylpyridinium ion‐induced cytotoxicity and reactive oxygen species production through miR‐15b‐5p/GSK3β axis in human dopaminergic SH‐SY5Y cells

Investigation of Long Non-coding RNA Expression Profiles in the Substantia Nigra of Parkinson's Disease

lncRNA PART1 mitigates MPP+-induced neuronal injury in SH-SY5Y cells via micRNA-106b-5p/MCL1 axis

LncRNA MEG3 inhibits cell proliferation and induces apoptosis in laryngeal cancer via miR‐23a/APAF‐1 axis

Upregulation of the lncRNA MEG3 improves cognitive impairment, alleviates neuronal damage, and inhibits activation of astrocytes in hippocampus tissues in Alzheimer's disease through inactivating the PI3K/Akt signaling pathway

Long Non-Coding Rna Meg3 Functions As A Tumour Suppressor And Has Prognostic Predictive Value In Human Pancreatic Cancer

Long non-coding RNA myocardial infarction-associated transcript promotes 1-Methyl-4-phenylpyridinium ion-induced neuronal inflammation and oxidative stress in Parkinson's disease through regulating microRNA-221-3p/ transforming growth factor /nuclear factor E2-related factor 2 axis